- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06454383
절제 불가능한 진행성 췌장암 환자의 젬시타빈 및 레플루노마이드
절제 불가능한 췌장암 환자를 대상으로 한 젬시타빈 및 레플루노미드의 1b상 연구
This phase Ib trial tests the safety, side effects, and best dose of leflunomide in combination with gemcitabine in treating patients with pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and cannot be removed by surgery (unresectable). Improving the effectiveness of gemcitabine without increasing side effects could lead to a greater impact for pancreatic cancer patients' survival and quality of life. Gemcitabine is commonly used as a first-line chemotherapy treatment for pancreatic cancer. Leflunomide is a drug approved for use against rheumatoid arthritis that is being looked at as a cancer treatment option. It has shown promising results when combined with gemcitabine. Giving gemcitabine in combination with leflunomide may be safe and effective in treating patients with advanced unresectable pancreatic cancer.
연구 개요
상태
상세 설명
PRIMARY OBJECTIVE:
I. To evaluate the safety and tolerability of gemcitabine in combination with leflunomide and determine the recommended Phase 2 dose (RP2D) of the combination.
SECONDARY OBJECTIVES:
I. To evaluate the progression-free (PFS) and overall survival (OS). II. To evaluate the overall response rate (ORR), including confirmed and unconfirmed, complete and partial response and stable disease.
III. To describe quality of life utilizing the Functional Assessment of Cancer Therapy: General (FACT-G) questionnaire.
EXPLORATORY OBJECTIVES:
I. To describe the pharmacokinetic profile of leflunomide when given in combination with gemcitabine.
II. To examine the relationship between pharmacokinetics and disease progression.
OUTLINE:
Patients receive gemcitabine intravenously (IV) over 30 minutes on days 1, 8, and 15 of each cycle and leflunomide orally (PO) once daily (QD) on days -3 to -1 prior to cycle 1 and days 1-28 of each cycle thereafter. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive cholestyramine PO three times a day (TID) for 11 days at the end of treatment in the absence of unacceptable toxicity. Patients also undergo computed tomography (CT), magnetic resonance imaging (MRI), or other imaging scans as clinically indicated throughout the study, as well as blood sample collection on study and during follow up.
After completion of study treatment, patients are followed up at 30 days then up to 1 year.
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Documented informed consent of the participant and/or legally authorized representative.
- Adult patients lacking capacity to consent may participate if they have a caretaker that could ensure oral medication compliance.
-
Agreement to allow the use of archival tissue from diagnostic tumor biopsies.
- If unavailable, exceptions may be granted with study principal investigator (PI) approval.
-
Age: ≥ 18 years.
-
Eastern Cooperative Oncology Group (ECOG) ≤ 1.
-
Subjects must have histologically or cytologically confirmed diagnosis of advanced unresectable pancreatic ductal adenocarcinoma (PDA).
-
Measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
-
Potential patients must have plans of receiving single agent gemcitabine.
-
Fully recovered from the acute toxic effects (except alopecia or neuropathy) to ≤ grade 1 to prior anti-cancer therapy.
-
Without bone marrow involvement: Absolute neutrophil count (ANC) ≥ 1,500/mm^3 NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement.
-
Without bone marrow involvement: Platelets ≥ 100,000/mm^3 NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement.
-
Hemoglobin ≥ 9g/dL NOTE: Red blood cell transfusions are not permitted within 14 days of hemoglobin assessment unless cytopenia is secondary to disease involvement.
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 x ULN (unless has Gilbert's disease total bilirubin ≤ 3 x ULN)
-
Aspartate aminotransferase (AST) ≤ 1.5 x ULN OR if liver metastases ≤ 3 x ULN
-
Alanine aminotransferase (ALT) ≤ 1.5 x ULN OR if liver metastases ≤ 2 x ULN
-
Creatinine ≤ 1.5 x ULN OR creatinine clearance (Cockcroft Gault) of ≥ 50 mL/min for participants with a creatinine level of > 1.5 x ULN.
-
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
-
Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of gemcitabine therapy for women and at least 3 months after the last dose of gemcitabine therapy for men, and/or undergo drug elimination of leflunomide at end of treatment until leflunomide is undetectable in the plasma.
- Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).
Exclusion Criteria:
- Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy.
- Drugs metabolized by CYP2C8, CYP1A2, BCRP, OATP1B1/B3, and OAT3 transporters within 21 days prior to day 1 of protocol therapy.
- Herbal medications (excluding cannabidiol [CBD]).
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.
- Issues with tolerating oral medication (e.g. inability to swallow pills, malabsorption issues, ongoing nausea or vomiting).
- Positive for tuberculosis or latent tuberculosis (TB).
- Active diarrhea.
- Clinically significant uncontrolled illness.
- Active infection requiring antibiotics.
- Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection. (*If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable.)
- Diagnosis of Gilbert's disease.
- Prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated 5 or more years prior to study entry with no subsequent evidence of recurrence. Patients with a history of low grade (Gleason score ≤ 6 = Gleason group 1) localized prostate cancer will be eligible even if diagnosed less than 5 years prior to study entry. Other malignancies with low probability of recurrence may be allowed with PI approval.
- Females only: Pregnant or breastfeeding.
- Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Treatment (gemcitabine, leflunomide)
Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 of each cycle and leflunomide PO QD on days -3 to -1 prior to cycle 1 and days 1-28 of each cycle thereafter. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive cholestyramine PO TID for 11 days at the end of treatment in the absence of unacceptable toxicity. Patients also undergo CT, MRI, or other imaging scans as clinically indicated throughout the study, as well as blood sample collection on study and during follow up. |
Undergo blood sample collection
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Given IV
다른 이름들:
Given PO
다른 이름들:
Undergo imaging scans
다른 이름들:
Given PO
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Dose limiting toxicities (DLTs)
기간: Up to 28 days (cycle 1)
|
Toxicities will be graded according to Common Terminology Criteria for Adverse Events version 5.0. |
Up to 28 days (cycle 1)
|
|
Incidence of adverse events
기간: Up to 30 days after completion of study treatment
|
Toxicities will be graded according to Common Terminology Criteria for Adverse Events version 5.0. |
Up to 30 days after completion of study treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free survival (PFS)
기간: From start of protocol treatment until progression or death, and if neither event occur, the patient is at the time of last contact, assessed up to 1 year after completion of study treatment
|
PFS will be estimated using the Kaplan-Meier product-limit method. |
From start of protocol treatment until progression or death, and if neither event occur, the patient is at the time of last contact, assessed up to 1 year after completion of study treatment
|
|
Overall survival (OS)
기간: From start of protocol treatment until death, and if the patient is alive, the patient is censored at time of last contact, assessed up to 1 year after completion of study treatment
|
OS will be estimated using the Kaplan-Meier product limit method. |
From start of protocol treatment until death, and if the patient is alive, the patient is censored at time of last contact, assessed up to 1 year after completion of study treatment
|
|
Overall response rate (ORR)
기간: Up to 1 year after completion of study treatment
|
ORR will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. |
Up to 1 year after completion of study treatment
|
|
Change in quality of life (QOL)
기간: Baseline to 1 year after completion of study treatment
|
Change in QOL will be measured by the Functional Assessment of Cancer Therapy: General (FACT-G) questionnaire. |
Baseline to 1 year after completion of study treatment
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Vincent Chung, City of Hope Medical Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 내분비계 질환
- 부위별 신생물
- 신생물
- 소화계 신생물
- 소화기계 질환
- 내분비샘 신생물
- 췌장 질환
- 췌장 신생물
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 조사 기술
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- Azoles
- 물리적 현상
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 중합체
- 거대 분자 물질
- 생체 의학 및 치과 재료
- 제조 된 재료
- 기술, 산업 및 농업
- 화학 기술, 분석
- 스펙트럼 분석
- 전자기 현상
- 자기 현상
- 전자기 방사선
- 방사
- 방사선, 이온화
- 다색
- 플라스틱
- Isoxazoles
- 레플루노마이드
- 젬시타빈
- 콜레스티라민 수지
- 시편 처리
- 자기 공명 분광법
- 엑스선
기타 연구 ID 번호
- 23540
- P30CA033572 (미국 NIH 보조금/계약)
- 23540 (기타 식별자: City of Hope Medical Center)
- NCI-2024-04359 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .